CJC-1295 no DAC 10mg — Mod GRF (1-29), HPLC ≥98%

Zoom

49,00 €

Tax included • Free delivery from 99€

+2,45 € in loyalty cashback, with an account. Create my account

19 in stock, ready to ship

Next dispatch: Saturday, October 3

In stock in France

Subscription

44,10 €-10 %instead of 49,00 €

-10 % for life on each cyclePause, skip or cancel in 1 clickNo commitment, no hidden fees

Your complete kit

10mg vialIncluded
Bacteriostatic waterAdd
1 ml syringesAdd

The vial alone cannot be used as is. One sealed vial of CJC-1295 NO DAC 10mg, lyophilised, without individual labelling.

Don't forget the essentials

Eau Bactériostatique

7,90 €

Seringue de précision 1ml 29Gx107,90 €

Lingettes alcool isopropylique 70%x103,90 €

Cartouches 3 mlx59,90 €

Aiguilles Stylo Injecteurx1010,90 €

Frequently bought together

Ipamorelin 5mg27,00 €

KPV 10mg34,00 €

Cagrilintide 5mg35,00 €

GHK-Cu 100mg49,00 €

CJC-1295 without DAC, also known as Mod GRF (1-29), is a synthetic analogue of the first 29 amino acids of human GHRH — the fragment that carries the hormone's activity on its own.

Four substitutions set it apart from the natural sequence: D-Ala2, which protects it from DPP-4 degradation, plus Gln8, Ala15 and Leu27, which improve its stability. The result is a half-life of about thirty minutes, against a few minutes for native GHRH.

The whole difference with CJC-1295 with DAC lies in what is missing: the Drug Affinity Complex, which binds the molecule to albumin and stretches its half-life to several days. Without it, action stays brief — and that is precisely what protocols seeking to preserve the natural pulsatility of growth hormone secretion are after, rather than flattening it.

This vial delivers 10 mg of CJC-1295 without DAC at HPLC purity of at least 98%. For research use only.

Science

01
Mechanism of action

GHRH acts on the GHRH-R receptor of somatotroph cells in the anterior pituitary, a G-protein coupled receptor. Its activation raises intracellular cyclic AMP, activates protein kinase A and triggers both the release of stored growth hormone and the transcription of its gene.

The D-Ala2 modification is the decisive one: it blocks the cleavage site of dipeptidyl peptidase-4, the enzyme that inactivates native GHRH within minutes. The other three substitutions limit oxidation and aggregation in solution.

The point that explains the frequent pairing with a GHRP such as Ipamorelin: the two families act on distinct receptors — GHRH-R on one side, GHS-R1a on the other — and through different signalling pathways. The literature describes a response greater than the sum of each taken alone, which is the documented basis for this combination.

By keeping a short action, the DAC-free analogue also lets somatostatin, the axis's physiological brake, express itself, which preserves the pulsatile character of secretion.

Clinical data

02Clinical studies

GHRH has been characterised since the 1980s and its 1-29 fragment, the shortest to retain full activity, is the basis of several analogues. Sermorelin, unmodified GHRH 1-29, was marketed as a diagnostic agent for somatotroph function, which solidly documents the overall mechanism.

Work on CJC-1295 clearly distinguishes the two versions. The version with DAC was the subject of early-phase trials showing sustained IGF-1 elevation over several days. The version without DAC, this one, is by contrast overwhelmingly documented in research literature and preclinical work, not by dedicated clinical trials.

Pairing with a GHRP is the best-described point: the combined effect of a GHRH analogue and a secretagogue acting on GHS-R1a is reported as greater than each taken alone, which remains consistent with the duality of signalling pathways.

No authority has evaluated CJC-1295 without DAC for therapeutic use. It is a research product.

No references yet for this peptide — search PubMed for associated scientific literature.

The listed studies are provided for documentation and research purposes only. They do not constitute a therapeutic indication nor a recommendation for human use. This product is strictly for laboratory use only (RUO).

Lab workflow

03
Research protocols

Reconstitution. The 10 mg vial is reconstituted with 3 ml of bacteriostatic water, giving a 3.33 mg/ml solution. On a U-100 insulin syringe, 7.5 units then equal 250 mcg and 3 units equal 100 mcg. An alternative volume of 2 ml gives 5 mg/ml, for those wishing to reduce injected volume.

The vial is then full up to the neck: this is normal, it holds 3 ml at most. The 3 ml bacteriostatic water vial is enough.

Procedure: room temperature, septum disinfected with 70% isopropyl alcohol, slow injection along the wall, then gentle rolling between the palms until fully dissolved. Never shake vigorously.

Reported orders of magnitude. Research literature typically mentions 100 mcg per administration, one to three times daily, often away from lipid-rich meals which blunt the response. At 100 mcg three times daily, i.e. 300 mcg per day, a 10 mg vial represents roughly 33 days. At 100 mcg once daily, roughly 100 days. These figures are reported, not recommended.

Documented pairing. CJC-1295 without DAC combined with Ipamorelin is the most described secretagogue protocol in research literature, the two molecules acting on different receptors.

Reconstitution for this format (10 mg)Standard volumes used in laboratory settings

Water added	Concentration	Reading marker
1 ml	10 mg/ml	10 UI = 1 mg
3 ml	3,33 mg/ml	40 UI = 1,33 mg

The volume of water does not change the product, only its concentration. Introduce the water slowly along the vial wall, never directly onto the lyophilisate, then swirl without shaking. Markers given on a 1 ml syringe graduated in 100 units.

Asepsis

Disinfect surfaces and stoppers (70% alcohol).

Solvent

Draw the required volume of bacteriostatic water.

Introduction

Inject gently against the vial wall (avoid direct jet on powder).

Solubilization

Roll the vial gently. Do not shake vigorously (degradation risk).

Solution storageOnce reconstituted: 2-8°C (refrigerator).

WarningTheoretical tool for chemical handling. Does not constitute medical advice.

I open the dilution calculator

What is normal on arrivalThe observations that worry customers, and are not defects

The amount of powder looks tiny. A lyophilisate takes up a few millimetres at the bottom of the vial, sometimes just a translucent film. The stated weight is there.
The powder is compact, stuck to the wall or to the stopper. Transport moves the freeze-dried cake around. It changes nothing to reconstitution.
The vial carries no individual label. That is our standard packaging, not a downgraded vial.
After reconstitution, deposits or filaments appear. This is common, especially with small molecules. Let it settle and roll the vial between your palms, never shake it.
The parcel is plain. Nothing on the outside indicates the contents or the brand name.

What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.

Handling

04Storage & handling

Unreconstituted lyophilised vial: stable for several months between 2 and 8 °C, several years at -20 °C, protected from light. Ambient-temperature transport does not degrade it.

After reconstitution: refrigerated between 2 and 8 °C, protected from light. The 0.9% benzyl alcohol in bacteriostatic water allows repeated draws over several weeks. Never freeze a reconstituted solution.

At 3 ml for 10 mg, a vial is drawn from over a long period: this is precisely the case where asepsis quality at each draw matters most. A fresh needle every time, a disinfected septum every time.

01How much water to reconstitute the 10 mg vial?

3 ml of bacteriostatic water, giving 3.33 mg/ml. On a U-100 syringe, 100 mcg then reads as 3 units and 250 mcg as 7.5 units. The vial is then full up to the neck: this is normal, it holds 3 ml at most. The 3 ml water vial is enough.

02What is the difference with CJC-1295 with DAC?

The affinity complex, and nothing else. With DAC, the molecule binds albumin and its half-life reaches several days, producing continuous elevation. Without DAC, it acts over about thirty minutes, which preserves the natural pulsatility of secretion. Two different profiles, not an inferior version.

03Why is it so often paired with Ipamorelin?

Because both act on distinct receptors: GHRH-R for CJC-1295, GHS-R1a for Ipamorelin. Research literature describes a combined response greater than each taken alone, which is why this pair is the most documented secretagogue protocol.

04How long does a 10 mg vial last?

10 mg is 10,000 mcg. At the quantities reported in the literature, 100 mcg three times daily i.e. 300 mcg per day, a vial represents roughly 33 days. At 100 mcg once daily, roughly 100 days. Actual autonomy depends on the chosen scheme.

05Are Mod GRF (1-29) and CJC-1295 without DAC the same thing?

Yes. Both names designate the same peptide: GHRH 1-29 modified at four positions, without affinity complex. "Mod GRF (1-29)" is the descriptive name, "CJC-1295 without DAC" the most widespread commercial one. The confusion arises because the CJC-1295 name also designates the DAC version, which is a different molecule.

06Must the solution be perfectly clear?

A light, uniform haze may appear and is not a defect. What justifies discarding a vial is particles that stay in suspension, a deposit that will not redissolve despite cold rest, or a yellow colour.

Benchmark

Similar peptides

Against CJC-1295 with DAC. Same base peptide, one difference: the affinity complex binding the molecule to albumin. With DAC, half-life extends to several days and elevation becomes continuous — at the cost of pulsatility. Without DAC, action lasts about thirty minutes and lets somatostatin play its braking role. This is not a degraded version, it is a profile choice.

Against Ipamorelin. These are different families, and that is why they are paired: GHRH acts on GHRH-R, Ipamorelin is a GHRP acting on GHS-R1a. Two receptors, two pathways, a combined response described as greater than the sum of both.

Against Tesamorelin. Tesamorelin is also a GHRH analogue, but it is the only one in the class with FDA approval, obtained in 2010 for a specific indication. It is stabilised differently and its documented profile is clinical where CJC-1295 without DAC remains preclinical.

Against IGF-1 LR3. Opposite levels of action: CJC-1295 acts upstream on the pituitary and respects feedback loops, IGF-1 LR3 acts downstream, directly on the IGF-1R receptor.

CJC-1295 NO DAC 10mg Croissance musculaire

Growth Factors

01
Mechanism of action

02Clinical studies

03
Research protocols

Asepsis

Solvent

Introduction

Solubilization

04Storage & handling

Similar peptides

Growth Factors

Product information

Asepsis

Solvent

Introduction

Solubilization

Complementary reagents